
Enanta Doses First Patient in Phase 1 Trial of EDP-978 for Urticaria
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria Enanta Pharmaceuticals, Inc., a clinical-stage…












